Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

NCT: NCT06608823 · RECRUITING

NCT IDNCT06608823
StatusRECRUITING
Start Date2025-06-18
SponsorJenaValve Technology, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

To demonstrate non-inferiority of the Trilogy Transcatheter Heart Valve (THV) System compared with surgical aortic valve replacement (SAVR) for treatment of subjects with clinically significant native aortic regurgitation (AR)

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑